Drug Profile
Dendritic cell vaccine - SBI Biotech
Alternative Names: Immunocell Therapy Project - SBI BiotechLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator SBI Biotech
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 24 Sep 2015 No recent reports of development identified - Phase-I/II for Malignant melanoma in Japan (SC)
- 24 Sep 2015 No recent reports of development identified - Preclinical for Solid tumours in Japan (unspecified route)
- 17 Aug 2012 SBI Biotech completes enrolment in its phase I/II trial for Malignant melanoma in Japan (UMIN000004617)